Joshua P Havens
YOU?
Author Swipe
View article: Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series
Long-acting Cabotegravir/Rilpivirine for Treatment of HIV During Pregnancy: A Case Series Open
We present pharmacokinetic data on long-acting cabotegravir/rilpivirine (LA CAB/RPV) from two patients during their second and third trimesters. Monthly LA CAB/RPV dosing maintained concentrations above the proposed efficacy thresholds whi…
View article: Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report Open
Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case o…
View article: Implementation of an Online Drug–Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19
Implementation of an Online Drug–Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19 Open
Background Ensitrelvir is an antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with associated drug–drug interactions (DDIs) through CYP3A, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), …
View article: Utilization of Doxycycline Postexposure Prophylaxis at a Midwestern United States HIV/PrEP Clinic
Utilization of Doxycycline Postexposure Prophylaxis at a Midwestern United States HIV/PrEP Clinic Open
Appropriate, protocol-adherent, doxycycline postexposure prophylaxis prescribing occurred for 70% of prescriptions from our clinic. Most of the nonadherent prescribing was due to missed sexually transmitted infection screenings (89%). As u…
View article: Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders
Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders Open
Background The BASE study (NCT03998176), a phase 4, 48-week (W), single-arm, prospective trial, revealed that the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV and substance use disorders (PWH/SUD) was…
View article: Doxycycline as Post-Exposure Prophylaxis: Awareness, Beliefs, and Interest Among Patients with and at Risk for HIV
Doxycycline as Post-Exposure Prophylaxis: Awareness, Beliefs, and Interest Among Patients with and at Risk for HIV Open
View article: Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report
Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report Open
As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug–drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with in…
View article: Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States
Acceptability, Feasibility, and Appropriateness of Implementation of Long-acting Injectable Antiretrovirals: A National Survey of Ryan White Clinics in the United States Open
Background The approval of long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) heightened the urgency of ensuring effective implementation. Our study assesses readiness and barriers to implement LAI CAB/RPV across Ryan White–fund…
View article: Patient perspectives of antiretroviral pharmacy services: A cross-sectional cohort study
Patient perspectives of antiretroviral pharmacy services: A cross-sectional cohort study Open
Background Adherence to antiretroviral therapy (ART) remains the main predictor of sustained HIV virologic suppression for people with HIV (PWH). Mail-order pharmacy services are often offered to patients as an alternative option to tradit…
View article: Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study
Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study Open
Background People with human immunodeficiency virus (HIV) and substance use disorder (PWH/SUD) are at higher risk of nonadherence to antiretroviral therapy. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) exhibits high rates of e…
View article: Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia
Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia Open
Background The use of adherence measures as markers for virologic failure (VF) has been studied. Yet, there is currently no single adherence metric recommended for VF. Antiretroviral prescription refill histories, for people living with hu…
View article: Customized blister packaging for patients living with HIV: assessment of patient attitudes and satisfaction
Customized blister packaging for patients living with HIV: assessment of patient attitudes and satisfaction Open
Adherence to antiretroviral medication results in reduced HIV transmission and improved health outcomes, yet challenges with medication adherence remain. A Collaborative Care Program was developed with a community pharmacy integrating a mu…
View article: Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis
Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Open
We report a case of acute weight gain after switching from emtricitabine/tenofovir disoproxil to emtricitabine/tenofovir alafenamide for human immunodeficiency virus pre-exposure prophylaxis.
View article: HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety Open
View article: Impact of Pharmacy Type on HIV Viral Suppression: A Retrospective Cross-Sectional Cohort Study
Impact of Pharmacy Type on HIV Viral Suppression: A Retrospective Cross-Sectional Cohort Study Open
Background People with HIV (PWH) use various pharmacy types beyond traditional local pharmacies. Some specialized pharmacies offer additive adherence services such as refill reminders, expedited delivery, and adherence packaging. Methods T…
View article: Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection Open
BACKGROUND Short-course hepatitis C (HCV) treatment with direct-acting antivirals (DAA) under 8 weeks in duration has resulted in variable efficacy rates in HCV mono-infection. Further, DAA courses under 8 weeks in duration have not been s…
View article: Response to Dong et al.
Response to Dong et al. Open
View article: Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy
Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy Open
Background Transwomen have an increased risk of HIV acquisition compared with other adults. Drug–drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transw…
View article: Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review Open
View article: Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States
Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States Open
Background Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in the PrEP care process…
View article: Midwest pharmacists’ familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV
Midwest pharmacists’ familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV Open
Pharmacist respondents in Nebraska and Iowa had limited familiarity and experience with PrEP, but most indicated willingness to provide PrEP through collaborative practice agreements after additional training. Provision of PrEP-focused con…
View article: 1294. Acceptability and Feasibility of a Pharmacist-led Pre-exposure Prophylaxis Program in the Midwestern United States
1294. Acceptability and Feasibility of a Pharmacist-led Pre-exposure Prophylaxis Program in the Midwestern United States Open
Background Despite evidence that HIV pre-exposure prophylaxis (PrEP) substantially reduces the risk of infection in at-risk populations, significant barriers exist to its prescription and use. Utilizing pharmacists may help increase patien…
View article: A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction Open